Browsing by Autor "Thaynara Maria Maran de Souza"

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • Thumbnail Image
    Item type: Item ,
    Epidemiological profile and clinical characteristics of patients with intestinal inflammatory disease
    (Thieme Medical Publishers (Germany), 2017) Jhelly Aparecida Valcanaia Arantes; Carlos Henrique Marques dos Santos; Breno Matos Delfino; Bruno Alexandre da Silva; Rafaela Maria Maran de Souza; Thaynara Maria Maran de Souza; Isabella Demeis Flávio; Caroline Gil Ferreira; Samuel Bellin Gomes da Cruz
    Abstract According to several epidemiological studies, there is a significant increase in cases of inflammatory disease in developing countries. Objective To describe epidemiological data and clinical features of patients with inflammatory bowel disease in patients enrolled in Campo Grande, MS. Method A retrospective descriptive study with a database analysis of patients who were enrolled and renewed their process in the Exceptional Medications Program of the Health Department from January 2008 to December 2016. Results 423 patients participated in the study, 260 women and 163 men. Of these, 238 patients had Crohn's disease and 185 had ulcerative rectocolitis. The patients’ mean age was 46 years. The most commonly used medication for both diseases was mesalazine and 34.3% of the patients needed to switch their medication during the treatment, most of them with Crohn's disease. In Crohn's patients, the most affected segment was the colon (40.6%) and in patients with ulcerative rectocolitis the entire large intestine was involved (78.8%) was more common. Of the total number of patients, 10.8% of the women and 18.4% of the men needed to use an anti-TNF. Conclusion Most people on treatment for IBD are female, with a mean age of 46 years and suffering from Crohn's disease. The most affected segments were the entire large intestine in URC cases and the colon in Crohn's disease cases. Mesalazine was the most used drug in both diseases. There was more drug replacement in Crohn's disease patients. In Crohn's disease, younger patients used infliximab more frequently.